924 material Form 8-K filings that 737 companies we cover made with the SEC in January 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Merit Medical said preliminary, unaudited fourth-quarter 2025 revenue was in the range of $389 million to $395 million, up about 10% to 11% from a year earlier, or 8% to 10% in constant currency. The company also named F. Ann Millner as Board Chair after founder Fred P. Lampropoulos resigned as director and Chair, which matters to shareholders because the company's leadership is changing while full 2025 results and 2026 guidance are still pending.
Preliminary Q4 2025 revenue of about $389 million to $395 million, up about 10% to 11% year over year; constant currency growth of about 8% to 10%
Lampropoulos resigned as director and Chair effective January 4, 2026, citing personal reasons, and is not leaving over any dispute or financial reporting matter
F. Ann Millner, formerly Lead Independent Director, became Chair effective January 5, 2026; the board also reduced its size from eleven to ten members
Full 2025 results and fiscal 2026 guidance are scheduled for release after the close on February 24, 2026
Pacira BioSciences reported preliminary, unaudited total revenue of $726.4 million for 2025, compared with $701.0 million in 2024, with fourth-quarter EXPAREL net product sales of $155.8 million. The figures are subject to adjustment, and the company expects to report complete fourth-quarter and full-year 2025 results and financial guidance later in the first quarter of 2026.
Full-year 2025 total revenue of $726.4 million, compared with $701.0 million in 2024.
Full-year EXPAREL net product sales of $575.1 million, compared with $549.0 million, with volume growth of 6 percent.
During the fourth quarter of 2025, the company repurchased 2.0 million shares for $50.0 million; $150.0 million remains on its authorization, which expires December 31, 2026.
CMC reported first-quarter fiscal 2026 net earnings of $177.3 million, or $1.58 per diluted share, on net sales of $2.1 billion, compared with a net loss of $175.7 million in the prior-year quarter, which included a $265.0 million litigation charge. Adjusted earnings were $206.2 million, or $1.84 per diluted share, versus $0.76 a year earlier. Management expects second-quarter core EBITDA to decline modestly from first-quarter levels due to seasonal slowdown, partly offset by the recently acquired precast businesses.
Net earnings of $177.3 million, or $1.58 per diluted share, versus a net loss of $175.7 million, or $1.54 per diluted share, a year earlier
Adjusted earnings of $206.2 million, or $1.84 per diluted share, versus $86.9 million, or $0.76 per diluted share, in the prior-year period
Second-quarter fiscal 2026 consolidated core EBITDA expected to decline modestly from first-quarter levels
Quarterly dividend of $0.18 per share declared January 5, 2026, payable February 2, 2026
Acuity Inc. reported fiscal first-quarter 2026 results for the quarter ended November 30, 2025. Net sales rose 20.2% to $1.14 billion, operating profit rose 20.3% to $160.4 million, and diluted EPS rose 14.0% to $3.82. The release does not include updated financial guidance, and part of the sales growth comes from three months of QSC performance within the Acuity Intelligent Spaces segment.
Net sales were $1,143.7 million versus $951.6 million a year earlier, an increase of $192.1 million or 20.2%.
Diluted EPS was $3.82 versus $3.35; adjusted diluted EPS was $4.69 versus $3.97.
Acuity Intelligent Spaces net sales were $257.4 million versus $73.5 million, including three months of QSC performance.
During the quarter the company repurchased about 77,000 shares for about $28 million and repaid $100.0 million of term-loan borrowings.
TD SYNNEX reported fiscal fourth-quarter 2025 results for the period ended November 30, 2025, with revenue of $17.4 billion, up 9.7% year over year and above the high end of its outlook. GAAP diluted EPS rose to $3.04 from $2.29, and non-GAAP diluted EPS was $3.83, up 24.0%. The company also declared a $0.48 quarterly dividend, up 9% year over year, and guided fiscal first-quarter 2026 non-GAAP diluted EPS to $3.00 to $3.50.
Q4 FY25 revenue was $17.4 billion, up 9.7%, and above the high end of the company's outlook; up 7.5% in constant currency.
GAAP diluted EPS was $3.04 versus $2.29; non-GAAP diluted EPS was $3.83 versus $3.09.
Q1 FY26 outlook: revenue of $15.1 to $15.9 billion and non-GAAP diluted EPS of $3.00 to $3.50.
Quarterly dividend of $0.48 per share, payable January 30, 2026, to holders of record as of January 16, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.